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This journal is ª The Royal Society ofDevelopment of a DNA aptamer for direct and selective
homocysteine detection in human serum†
Maureen McKeague, Amanda Foster, Yasmine Miguel, Amanda Giamberardino,
Cle´ment Verdin, Joshua Y. S. Chan and Maria C. DeRosa*
L-Homocysteine has been an amino acid intermediate of interest for over 20 years due to its implication in
various adverse health conditions, including cardiovascular disease. Here, we report the ﬁrst in vitro
selection and application of high aﬃnity aptamers for the target L-homocysteine. Two novel aptamer
sequences were selected following 8 rounds of selection that displayed high aﬃnity binding and
selectivity to homocysteine compared to other amino acids. One of the selected aptamers, Hcy 8 (KD ¼
600  300 nM), was used to develop a gold-nanoparticle biosensor capable of sensitive and selective
homocysteine detection in human serum, with a limit of detection of 0.5 mM and a linear range of
0.5–3.0 mM. This biosensor allows rapid detection of free homocysteine in human serum samples at low
cost, with little preparation time and could be adapted to be part of a point-of-care screening method.Introduction
L-Homocysteine (Hcy) is an amino acid intermediate produced at
the intersection of two major biochemical pathways, where it is
irreversibly transformed via the transsulfuration pathway into
cysteine or is remethylated back to methionine.1 The proposed
upper reference limit for plasma homocysteine levels in adults
leading a healthy lifestyle or taking adequate vitamins is 12 mM.2
Increased homocysteine levels have been shown to be associated
with several diseases including cardiovascular disease,3 Alz-
heimer's disease,4 dementia,5 pregnancy complications and birth
defects,6 osteoporosis,7 and cancer.1 Additionally, homocystinuria
is a rare autosomal recessive condition where homocysteine
plasma concentrations are severe (>100 mM). Homocystinuria
results in a high risk of vascular disease if le untreated. Indi-
viduals that are homozygous for homocystinuria also experience
ocular, skeletal, and neurologic complications.8 As a result, rapid,
sensitive, and selective detection of homocysteine is of great
interest for point-of-care screening and diagnosis.
Several analytical techniques have been developed for the
detection of homocysteine. These include high performance
liquid chromatography (HPLC) separation-based methods, gas
chromatography/mass spectrometry (GC/MS), capillary electro-
phoresis (CE), electrochemical detection, and capillary zone
electrophoresis (CZE). Reviews on these methods have been
previously published.9 These methods are typically sensitive but1125 Colonel By Drive, Ottawa, ON, K1S
on.ca; Fax: +1-613-520-3749; Tel: +1-613-
(ESI) available: Extended experimental
diction, and sample binding isotherm.
Chemistry 2013time-consuming and costly, thus necessitating a simple, inex-
pensive screen that could be used at the point-of-care and could
serve as a tool for decision-making about further testing. Some
methods have been developed that utilize antibodies as eﬀec-
tive molecular recognition agents. Examples include chem-
iluminescence immunoassays, uorescence polarization
immunoassays and ELISA.10 While useful, these assays are
costly and can be aﬀected by antibody cross-reactivity.11
Due to their optical properties, ease of use, and simple
synthesis, gold nanoparticles (AuNPs) have been incorporated
into a number of novel biosensor strategies. Aggregation of the
particles leads to an easily detectable color change of the
colloidal solution from red to blue. Gold nanoparticles have
been used to detect thiol-containing amino acids such as
cysteine and homocysteine.12 DNA-based gold nanoparticle
sensor strategies have also emerged13 since single-stranded
DNA (ssDNA) adsorbs onto the surface of gold nanoparticles
and can protect them from salt-induced aggregation.14 Based on
this principle, recent research has explored the detection of
cysteine using AuNPs and random ssDNA.15,16 The strong
interaction between the cysteine thiol and the gold surface
displaces the ssDNAmolecules adsorbed on the AuNPs, making
them once again susceptible to salt-induced aggregation
(facilitating a red-to-blue color change). Unfortunately, these
sensors lack specicity, and detect all thiol-containing
compounds.17,18 Thus, in order to exploit the simplicity of gold
nanoparticle assays for the rapid, and importantly, selective
detection of homocysteine, the incorporation of a specic
recognition element into this assay was required.
Aptamers are single-stranded nucleic acid ligands that are
discovered using an in vitro selection procedure called Systematic
Evolution of Ligands by EXponential enrichment (SELEX).1921RSC Adv., 2013, 3, 24415–24422 | 24415
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View Article OnlineLike antibodies, these synthetically derived molecular recogni-
tion probes are selective and able to bind to their target with high
aﬃnity. However, aptamers oﬀer several advantages over their
antibody counter-parts including improved stability, lower cost
and the ability to be modied at precise locations with reporter
molecules oenwithout aﬀecting binding activity. As a result, the
use of aptamers as recognition probes has emerged as a viable
approach in biosensing and therapeutics. However, the concep-
tual and technical challenges involved in small-molecule
aptamer development have resulted in relatively few new
aptamers for these targets.22 An RNA aptamer for S-adenosyl
homocysteine (SAH) with an aﬃnity of approximately 0.1 mM has
been reported.23 Despite the high aﬃnity, competition studies of
this aptamer revealed that adenine is the main contributor to
binding aﬃnity, with only a minor aptamer–target interaction at
the thioether of homocysteine. As a result, novel, stable DNA
aptamers selective for homocysteine that can be directly inte-
grated into useful detection systems are still required.
In this study, we report the rst isolation of aptamers that
recognize and bind to homocysteine with good aﬃnity and
selectivity, particularly notable based on the small size of the
target and the close structural resemblance to other amino
acids. The most promising of these aptamers was incorporated
into an unmodied AuNP-based colorimetric aptasensor
enabling selective detection of homocysteine over other amino
acids, including cysteine. Furthermore, the utility of this assay
for the rapid and direct detection of homocysteine in diluted
human serum samples is demonstrated.Experimental
Reagents and materials
Phosphoramidites and reagents for DNA synthesis were
obtained from Glen Research (Sterling, VA, USA). Standard
support columns and acetonitrile were purchased from Bio-
Automation (Plano, TX, USA). Ultra High Purity 5.0 argon was
purchased from Praxair. All PCR and electrophoresis compo-
nents were purchased from BioShop Canada (Burlington, ON,
Canada). L-Homocysteine thiolactone hydrochloride (L-HcyT),
DL-homocysteine, L-homocysteine (L-Hcy), L-cysteine, L-methio-
nine, L-serine, NHS Sepharose, 5,50-dithiobis-(2-nitrobenzoic
acid) (DTNB), human serum (from humanmale AB plasma) and
chemicals for buﬀering agents, nanoparticle synthesis and all
other purposes were purchased from Sigma-Aldrich. All water
used was Millipore Milli-Q deionized water at 18 MU cm.
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
(EDC) was received from Pierce (Rockford, Illinois, USA). Spin-X
cellulose acetate microcentrifuge lter tubes, Amicon-Ultra
0.5 mL 3 kDa centrifuge units and sulfo-NHS acetate were
purchased from Fisher Scientic Canada. ProMag 3 Series
carboxylic acid surfactant free magnetic beads were purchased
from Bangs Laboratories Inc (Fishers, IN, USA).Homocysteine-binding aptamers
L-Homocysteine-derivatized sepharose was prepared (see ESI
S1.1†) and used to select homocysteine-binding aptamers using24416 | RSC Adv., 2013, 3, 24415–24422amodied SELEX process. The starting DNA library was prepared
using standard phosphoramidite chemistry on a BioAutomation
Mermade 6 (Plano, Texas) using 200 nmol controlled pore glass
(CPG) columns with a 1000 A˚ pore size. The sequence is 96
nucleotides in length and contains a central region of 60
random nucleotides anked by two primer binding sites neces-
sary for PCR and cloning: 50-ATACCAGCTTATTCAATT-N60-AGA
TAGTAAGTGCAATCT-30. The following primers used for ampli-
cation and cloning of the selected oligonucleotides were
synthesized on a 1 mmol scale: Primer1: 50-ATACCAGCTTATT
CAATT-30 and Primer2: 50-AGATTGCACTTACTATCT-30. Modied
primers were also synthesized to allow for uorescent labeling of
the binding DNA and separation of strands on a denaturing
polyacrylamide gel: ModPrimer1: 50-6-FAM-ATACCAGCTTATT
CAATT-30 and ModPrimer2: 50-poly-dA20-HEG-AGATTGCACT
TACTATCT-30. HEG represents the hexaethylene glycol Spacer
Phosphoramide 18 (Glen Research). DNA was puried using
denaturing polyacrylamide gel electrophoresis (12%) followed by
extraction and clean-up with Amicon YM-3 Centrifugal Filter
Devices.
In vitro selection SELEX was performed as previously
described1921with several modications. Fresh aliquots of L-Hcy-
immobilized sepharose, unmodied sepharose or sepharose
modied with a counter-selection target (such as L-cysteine and
L-methionine) were pre-equilibrated by washing 10 times with 0.5
mL of homocysteine binding (HB) buﬀer, 50mM Tris-HCl, 5 mM
MgCl2, 0.5 M NaCl (pH 7.4), before each SELEX round. Prior to
the rst selection, the library (5 nmol) was suspended in 0.5 mL
of HB buﬀer and heated for 5 minutes at 95 C then cooled to
room temperature. In subsequent rounds, 200 pmol of pool
was used.
First, a negative selection was performed by incubating the
library with 250 mL of either unmodied column material
(rounds 1–5) or sepharose derivatized with counter-selection
target molecules (rounds 6–8) withmild shaking for 30minutes.
Only DNA lacking aﬃnity for the unmodied or counter-selec-
tion targets was collected by removal of supernatant following a
1 minute centrifugation at 5000 g. This library was subjected to
the same heating and cooling process described above, followed
by incubation with 100 mL of L-Hcy derivatized column for 30
minutes. Following incubation, sequences with little to no
aﬃnity for L-Hcy were removed with 10 washing steps using
200 mL of HB buﬀer. DNA bound to L-Hcy was then recovered
with several washes of 0.1 M Hcy (rounds 1 and 2), 3.5 M urea at
90 C (rounds 3–5) or 7 M urea at 90 C (rounds 6–8). These
conditions were chosen as the selection proceeded to accom-
modate the enrichment of the library. Recovery of putative
aptamers was performed until the uorescence of the elution
fractions was negligible. The recovery of aptamers, representing
the enrichment of the DNA library was assessed throughout the
rounds of selection by monitoring the percent of DNA library
binding to the L-Hcy column each round. DNA absorbance at
260 nm was measured using a Cary 300 BioUV-visible spectro-
photometer and uorescence (excitation 490 nm, emission
520 nm) was measured with a Fluorolog Fluorescence Spectro-
photometer (Horiba Jobin Yvon, USA) with a SpectrAcq
controller. The elution fractions were collected, puried usingThis journal is ª The Royal Society of Chemistry 2013
Table 1 Putative aptamer sequences obtained after 8 rounds of selection
against L-homocysteine
Sequence
50-ATACCAGCTTATTCAATT-N60-
AGATAGTAAGTGCAATCT-30
Hcy 8 ACCAGCACATTCGATTATACCAGCTTATTCAATTCACA
GCTATGTCCTATACCAGCTTATTCAATT
Hcy 10 GTGGAAAGCCGAATGTGATTAGGGACCAGTGGAGAAG
TAGTACGGACTGACCTCGCGTGTA
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View Article OnlineAmicon Ultra 3 kDa 0.5 mL centrifugal lters, and quantied
using UV-visible spectroscopy at 260 nm and/or using uores-
cence (ex: 490 nm, em: 520 nm). A total of 8 rounds were
performed.
The entire selected oligonucleotide library was amplied in
30 parallel PCR reactions for the rst round, in subsequent
rounds only 90% of the selected library was amplied with the
remaining 10% set aside for analysis and in case of PCR failure.
Each reaction consisted of 0.1 M Tris HCl pH 9, 50 mM KCl, 1%
Triton X-100, 1.9 mM MgCl2, 0.3 mM dNTP mix, 1 mM each
modied primer and 5 units of Taq DNA polymerase. The DNA
was initially melted for 10 minutes at 94.0 C, followed by 25
cycles of 94.0 C (1 minute), 47.0 C (1 minute) and 72.0 C
(1 minute). The nal extension occurred at 72.0 C for 10
minutes aer the last cycle. PCR products were dried down,
heated at 55 C for 5 minutes in the presence of formamide and
run on a 12% denaturing PAGE to separate the double stranded
product. The 50 uorescein-labeled DNA strands (the selected
sequences) could be identied using an Alpha Imager UV-illu-
minator. The corresponding DNA bands were cut from the gel
and extracted in 10 mM Tris HCl buﬀer, pH 7.4. The DNA was
then puried using the Amicon centrifugal lters, quantied
and re-suspended in HB buﬀer and could be used in the next
selection round.
The enriched DNA library obtained from SELEX round 8 was
PCR amplied using the unmodied primers (Primer1 and
Primer2) and cloned using the StrataClone PCR Cloning Kit
according to the manufacturer's protocol. Positive colonies
(white) were picked. DNA was prepared for sequencing by roll-
ing-circle amplication with the TempliPhi Amplication kit
using the protocol provided. The samples were sent for full
service sequencing at the University of Calgary Core DNA
Services (Calgary, AB, Canada). Sequences Hcy 8 and Hcy 10 (see
Table 1) were present multiple times in the sequencing pool.
Selected sequences Hcy 8 and Hcy 10 were then synthesized
with a 50 uorescein modier, 6-FAM, followed by PAGE puri-
cation. Aﬃnity chromatography assays were performed using
magnetic beads covalently modied with either $98%
L-homocysteine, L-methionine, or L-cysteine according to the
instructions from the beads manufacturer (see ESI S1.2†).
Varying concentrations of each Hcy 8 or Hcy 10 aptamer (1 nM–
50 mM) were prepared in HB buﬀer and heated to 95 C for 5
minutes and cooled to room temperature.
The magnetic beads assay was performed by incubating
100 mL of each aptamer sample with 2  108 L-Hcy-derivatized
beads in HB buﬀer for 30 minutes with mild shaking. Non-
binding DNA was removed with two 100 mL washes of HB buﬀer.This journal is ª The Royal Society of Chemistry 2013Following the removal of non-binding DNA, the receiving tube
was changed and the bound aptamers were eluted from the
column by washing twice with 90 CHB buﬀer. The DNA elution
fractions were pooled and the uorescence was measured
(excitation wavelength 490 nm; emission wavelength 520 nm).
The uorescence intensity (Fig. S1†) was plotted versus the
concentration of aptamer. The KD was determined by mini-
mizing the residual values between calculated and observed
experimental uorescence using the solver feature of Microso
Excel.24,25 The assay was performed in triplicate. For selectivity
tests, the aptamer sequences were incubated with the L-cysteine,
or L-methionine modied beads in the same way. One replicate
experiment for each aptamer and counter target was performed.Development of an aptamer–AuNP sensor
Gold nanoparticles were prepared using the Turkevich
method26 and characterized by UV-visible spectrometry, dis-
playing a lmax ¼ 522 nm (see ESI S1.3†). The assay was per-
formed as previously described with modications.27 Nine
samples of L-Hcy or L-cysteine in water were prepared at various
concentrations ranging from 500 nM to 6 mM. 243 mL of each
dilution of L-Hcy, L-cysteine or deionized water was added into
microcentrifuge tubes containing 6 mL of Hcy 8 (10 mM in
water). Aer a 30 minutes incubation period, 135 mL of the
AuNP solution (11 nM) was added, vortexed briey and allowed
to react for 5 minutes. 72 mL of 0.25 M NaCl was then added to
each microcentrifuge tube and allowed to incubate for a further
5 minutes. Each sample was then analyzed using UV-visible
spectrometry. The relative absorption ratio between 695 nm and
522 nm (A695/A522) was plotted against L-Hcy concentration. This
experiment was performed in triplicate.Human serum tests
The assay was performed as described above using samples
prepared in human serum as an alternative to deionized water.
10% human serum (from human male AB plasma) was
prepared by diluting 1 : 10 in deionized water. The amino acid
samples were dissolved in the 10% human serum samples.
500 mL of each concentration was ltered through Amicon-Ultra
0.5 mL 3 kDa centrifuge units. To determine the sensitivity of
the test, 500 nM to 6 mM of L-Hcy was prepared in 10% human
serum and tested with the AuNP assay. To assess the selectivity
of the assay, 1.5 mM of L-cysteine, L-methionine and L-serine
were prepared in 10% human serum and tested with the AuNP
assay. All tests were performed in triplicate.Results and discussion
Selection of homocysteine aptamers
The goals of this work were twofold: rstly to generate an
aptamer for homocysteine, and secondly to take a previously
non-selective gold nanoparticle detection platform and impart
selectivity by including this aptamer as a recognition element.
The rst goal of this project was particularly challenging given
the small size of the target and its structural similarities with
other amino acids.RSC Adv., 2013, 3, 24415–24422 | 24417
Fig. 1 Percent recovery of binding ssDNA to the L-Hcy immobilized sepharose
after each selection round. Beginning at round 6, counter-selections with
L-cysteine and L-methionine were performed prior to positive selection.
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View Article OnlineAs selection of aptamers towards small molecule targets
oen results in failure, careful consideration was made when
choosing the selection conditions and materials. The primers
chosen for this selection had been previously optimized for
SELEX experiments to minimize 30-mediated mis-priming and
primer dimers.28 A random region length of 60 nucleotides (nt)
was chosen to strike a balance between two competing factors:
shorter sequences are easier to synthesize and handle, while
longer sequences allow for a greater structural complexity and
possibly new functional motifs.29 Small molecules must be
tethered to a solid support matrix for selection; therefore, care
was taken to conrm suﬃcient immobilization of homocysteine
using the Ellman's test for free thiol groups. Negative selection
steps with unmodied column material were performed with
each SELEX round to ensure that sequences that displayed even
weak binding or partial recognition to the matrix were removed
from the selection library.30 While a negative selection is typi-
cally only performed at the beginning of SELEX, integrating this
additional step each round may reduce aptamer aﬃnity derived
from partial binding to the matrix and improve the likelihood
that the nal aptamers can eﬀectively measure free target in
solution. Additionally, counter-selections were performed to
remove any sequences from the library that could bind to
structurally similar molecules and therefore further enhance
the selectivity of the aptamers. Counter-selections using
L-cysteine and L-methionine were performed simultaneously in
rounds 6 through 8 once signicant enrichment of the library
was observed. These amino acids were chosen as they are the
only other amino acids with side chains containing a sulfur
atom; methionine consisting of a thioether and cysteine con-
taining a free sulydryl group. There are several other forms of
homocysteine found in the body. For example, in its most
common form, homocysteine is bound to the protein albumin
by a disulde linkage. Additionally, homocystine, which
consists of two homocysteine molecules bound by a disulde
bridge and the homocysteine–cysteine disulde (Hcy–Cys) can
occur. The extra counter-selection steps to gain selectivity
against these additional targets were not performed since total
homocysteine is typically measured, which requires a general
reduction step to convert all these forms to free homocysteine.2
To assess the enrichment of the library for target binding, as
well as to determine when increased stringency could be
applied to the selection, the percent binding of the DNA library
was carefully monitored aer each round using uorescence
and absorbance measurements (see Fig. 1). Beginning with
round 6, the counter-selections with L-cysteine and L-methio-
nine resulted in a reduction in the percentage of DNA eluted
from the L-Hcy immobilized column. This was not surprising as
L-cysteine, in particular, is structurally very similar to L-Hcy.
With the drastic reduction in the percent recovery of the library
(to <1%), it was expected that the resulting aptamers would have
a signicant preference in binding L-Hcy over the counter
targets L-cysteine and L-methionine.
Elution of target-binding sequences by aﬃnity with free
ligand was employed in the rst two rounds of selection, using
0.1 M L-Hcy. To ensure recovery of the highest aﬃnity candi-
dates, several other elution methods were employed in later24418 | RSC Adv., 2013, 3, 24415–24422rounds. In response to the subsequent library enrichment and
improvement in binding aﬃnity observed with each round,
elution with high concentrations of urea and heating were
tested. The most eﬀective conditions for elution were found to
be with 7 M urea at 90 C over several minutes, allowing full
recovery of putative aptamers (data not shown).Measuring aptamer aﬃnity and selectivity
Aer 8 rounds of selection, the pool was cloned and sequenced
in order to assess the presence of any high aﬃnity sequences.
Two unique sequences, Hcy 8 and Hcy 10 (Table 1) emerged
with high incidence in the sequencing results from the round 8
pool. Secondary structures of these sequences were predicted
using RNAstructure31 (see ESI Fig. S1†). Both structures appear
to be simple stem loops with bulges. Work is ongoing to
determine the putatitve binding pockets. Many KD determi-
nation methods are ineﬀective for measuring aptamer binding
to small molecules,22 and as L-homocysteine is one of the
smallest targets32 ever used in an aptamer selection (MW ¼
135.18 g mol1), determining the aﬃnity of the selected
aptamers was diﬃcult. Aﬃnity chromatography proved to be
the most eﬀective method to measure the aﬃnity for the
selected aptamers.
Aptamers selected using a solid support matrix may display
aﬃnity towards this matrix and/or the linker arm. Despite the
eﬀorts to eliminate any of this non-specic interaction by per-
forming multiple negative selections, it is not always possible to
avoid.33 Therefore, binding aﬃnity was tested using L-Hcy
derivatized magnetic beads instead of the sepharose used in the
selections. While there is a possibility for some non-specic
interaction with the beads, it is far less likely since these beads
were not used in the SELEX experiments. The measured KD
values of sequence Hcy 8 and Hcy 10 compared to counter
targets are listed in Table 2 (a sample binding isotherm can be
found in the ESI, see Fig. S2†). Notably, sequence Hcy 8 bound
to the L-Hcy beads with a KD in the low micromolar range
(approx. 600 nM). With the exception of one L-arginine aptamer,This journal is ª The Royal Society of Chemistry 2013
Table 2 Dissociation constants (KD) for sequences Hcy 8 and Hcy 10 obtained
using aﬃnity chromatography on target-immobilized magnetic beads (n ¼ 3).
Selectivity of Hcy 8 and 10 against similar amino acids is also noted (a sample
binding isotherm can be found in the ESI†)
Target
Dissociation constant KD (mM)
Hcy 8 Hcy 10
L-Hcy 0.6  0.3 1.2  0.7
L-Cysteine 22 91
L-Methionine 44 79
Fig. 2 Gold nanoparticle assay for target detection. (i) Single-stranded DNA
(such as an aptamer) coils around the sodium citrate stabilized AuNPs surface,
preventing salt-induced aggregation, therefore the colloid solution remains red
after salt addition. (ii) Analyte detection strategies (A) upon addition of high
concentrations of thiol-containing compounds, the gold–thiol interaction domi-
nates, releasing the ssDNA from the AuNPs. Therefore, salt-induced aggregation
returns and a blue-purple color is observed. (B) Upon addition of the aptamer's
target, the aptamer folds into a rigid structure around the target, preventing the
adsorption of the ssDNA on the AuNP surface. Therefore, salt-induced aggrega-
tion is possible and a blue-purple color is observed. While strategy A is eﬀective
for all thiols, strategy B should be selective for the aptamer's target, in this case,
homocysteine.
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View Article Onlinemost aptamers that bind to amino acids have KD values in the
high micromolar to millimolar range.22 Additionally, homo-
cysteine is one of the smallest DNA aptamer targets reported.
Given the challenge of nding aptamers for such a small
molecule, this is considered an excellent binding aﬃnity. While
both sequences bind to homocysteine beads with good aﬃnity,
Hcy 8 consistently resulted in the best KD value, in the low
micromolar range. However, the measured aﬃnities of both
sequences are suitable for detecting homocysteine within clin-
ically relevant ranges (high micromolar).
Both aptamer sequences were further tested for selectivity
against similar amino acid targets. Hcy 8 and Hcy 10 were found
to bind selectively to L-Hcy, displaying KD values that were
higher for L-cysteine and L-methionine (see Table 2). Even for
small molecules, aptamers with KD values in this range are
considered very weak (>20 mM). The binding curves produced
for these compounds did not reach a plateau for binding satu-
ration, therefore it is likely that both sequences bind to cysteine
or methionine with even lower aﬃnity. This selectivity indicates
that the Hcy aptamer is not merely interacting with the amino
acid backbone, characteristic of all amino acids. The thiol group
on the amino acid side chain is important in binding recogni-
tion. The observed selectivity emphasizes the power of in vitro
selection, in particular counter selection techniques. For
example, the selected RNA aptamer for theophylline was
counter-selected against caﬀeine and as a result displayed a
10 000 times weaker binding aﬃnity.34 In our case, counter
selections against methionine and cysteine proved successful.Principle of the AuNP sensor
It is well known that ssDNA can be used to stabilize AuNPs
against salt-induced aggregation by coiling around the AuNP
(Fig. 2(i)). Several studies have shown that due to the strong
gold–thiol interaction, cysteine and other thiol-containing
molecules are able to displace ssDNA molecules adsorbed on
AuNPs.16 This leaves the AuNPs once again susceptible to salt-
induced aggregation. Using these principles, several groups
have developed AuNP biosensors capable of detecting thiol-
based compounds at high concentrations (Fig. 2(ii)A).
Well-characterized aptamers for targets such as thrombin,35
adenosine,36 ochratoxin A,37 and dopamine27 have also been
used to protect AuNPs from aggregation. In the absence of
target, the aptamer remains unstructured and behaves like
ssDNA, coiling around the AuNPs. Upon the addition of target,This journal is ª The Royal Society of Chemistry 2013the tested aptamers preferentially bind to the target, folding
into a specic rigid tertiary structure.27 This limits the ability of
the aptamer to coil around the AuNPs; therefore, salt-induced
aggregation occurs (Fig. 2(ii)B). The ability of these aptamer–
nanoparticle sensing schemes to detect low concentrations of
their target provide precedent that a similar platform may be
applied to newly developed aptamers. We therefore tested
whether using the aptamers selected for L-Hcy, rather than
random ssDNA, would result in the aptamer–target interaction
dominating over the gold–thiol interaction, thus imparting
homocysteine selectivity to the typical thiol AuNP biosensor
(Fig. 2(ii)B).Biosensing of homocysteine
Figure 3A shows the UV-visible results of the developed AuNP
sensor under various conditions. The dispersed AuNPs have a
characteristic absorbance at 522 nm, corresponding to a red
color. Upon addition of salt, the nanoparticles aggregate and a
shi in absorbance to 695 nm (blue/violet) is seen. In the
absence of the aptamer, the addition of homocysteine (low or
high concentrations) alone do not aﬀect salt-induced aggrega-
tion. When the aptamer is added to the AuNPs, salt-induced
aggregation is prevented, as indicated by the presence of the
original 522 nm peak (and red color). With increasing concen-
trations of homocysteine, the gradual appearance of the peak at
695 nm occurs and a simultaneous decrease in the absorbance
at 522 nm, results in a color change from red to blue (Fig. 3A
and B). The response of the sensor was measured using the
relative absorption ratio between 695 nm and 522 nm (A695/A522)
plotted against L-Hcy concentration (Fig. 3C). We compared theRSC Adv., 2013, 3, 24415–24422 | 24419
Fig. 3 AuNP–aptamer biosensor (A) UV-visible results under various conditions.
The AuNPs have the characteristic absorbance at 522 nm, corresponding to a red
AuNP color (red trace). Upon addition of NaCl, the nanoparticles aggregate and a
shift in absorbance to 695 nm is seen (light blue trace). Homocysteine (Hcy) does
not aﬀect the salt-induced aggregation (dark blue trace) whereas the aptamer
(Apt) prevents aggregation (pink trace). Upon addition of Hcy with the aptamer,
aggregation is restored (green, purple and orange traces). (B) Using this
biosensor, an increase in Hcy concentration (L to R: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6
mM), results in aggregation and a change of color from red to blue. (C) Selectivity
of our aptamer–AuNP biosensor comparing L-homocysteine and L-cysteine at 3
mM, nearly a 4 fold signal enhancement is observed (p ¼ 0.0006).
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View Article Onlineresponse of our aptamer–AuNP biosensor to homocysteine and
cysteine. At 3 mM target, a signicant (4 fold) signal enhance-
ment is observed for detection of homocysteine over cysteine
(Fig. 3C). It is likely that within this region the aptamer–target
interaction dominates, resulting in the selective detection of
homocysteine compared to cysteine. At higher concentrations,
greater than 5 mM, the signal enhancement is lost. At these
concentrations, the gold–thiol interaction likely begins to
dominate and the sensor loses its selectivity for homocysteine.Fig. 4 AuNP–aptamer biosensor in 10% human serum (A) aptamer–AuNP
biosensor response to L-homocysteine in 10% human serum. The sensor has a
linear response between 0.5 mM and 3 mM (y ¼ 241 741x; R2 ¼ 0.985). (B)
Selectivity of the aptamer-AuNP biosensor at 1.5 mM target concentration. The
sensor is signiﬁcantly more sensitive to L-homocysteine compared to the other
amino acids (p ¼ 0.04).Homocysteine detection in human serum
A drawback of many rapid, selective and sensitive biosensors
reported in the literature is that they are not conducive to direct
use for measuring an analyte within a real-world sample.38
Indeed, there is only one published report to date of an
aptamer-based gold nanoparticle sensor that has been tested in
a complex matrix such as serum.39 While our sensor provides a
rapid and selective means for homocysteine detection at24420 | RSC Adv., 2013, 3, 24415–24422clinically relevant concentrations, its utility in measuring
homocysteine in human serum warranted investigation. High
concentrations of protein and other macromolecules found in
the serum are likely to interfere with detection. In particular, we
found that even small concentrations of human serum
(1 : 10 000 dilution) prevented the necessary salt-induced
aggregation. It is likely that the large proteins, lipids and
carbohydrates present in human serum40 interact with and coat
the nanoparticle surface, preventing aggregation.41 Even high
concentrations of NaCl (up to 10 mM) could not restore aggre-
gation (data not shown). However, a rapid ltration step allowed
removal of these large interfering macromolecules, without
aﬀecting homocysteine concentration. Following this step, a
linear correlation between aggregation, measured as (A695/A522)
and homocysteine concentration was found from 0.5 mM to
3 mM with a limit of detection (LOD) of 0.5 mM (3s), see Fig. 4A,
indicating that the biosensor is useful in direct analysis of
homocysteine. The linear dynamic range of the sensor is
comparable to that reported in immunoassay and HPLC
formats; however, detection with our sensor is complete within
20minutes whereas most immunoassay formats require over an
hour.10 This assay also modestly improves on sample prepara-
tion time compared to typical HPLC detection methods, whereThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinesample derivitization, clean-up and chromatography require
30–45 minutes.
Moreover, the use of an aptamer rather than an antibody
reduces the costs and improves the shelf-life for the assay
compared to ELISA methods. The cost of the materials for this
AuNP test, for example the AuNPs and DNA, from common
vendors such as Sigma Aldrich and Integrated DNA Technologies
is approximately $150 for 100 samples. In contrast, ELISA kits for
homocysteine detection are typically around $1000 for 100
assays. While the cost of consumables for HPLC detection-based
methods are relatively low, the need for sophisticated equipment
and highly trained personnel drastically increases the cost of
these methods. While some other aptamer–AuNP sensors report
improved LODs over what is seen here (0.5 mM vs. high nano-
molar range), the sensitivity of this sensor is suitable for detect-
ing homocysteine within clinically relevant ranges, i.e. aer the
ltration and 1 : 10 dilution, values above the upper reference
limit of 12 mM would fall within the assay's linear range. This
assay could therefore serve as a low cost, point of care screen that
could inform whether further testing is warranted.
Furthermore, the majority of the aptamers used in these
sensors use minimal aptamers of less than 58 nucleotides in
length. Our aptamer, Hcy 8 is 102 nt in length. Chen et al.16
found that longer ssDNA, even 30 nt in length compared to 24 nt
in length, resulted in signicant reduction in sensitivity of these
biosensors. By performing truncation experiments, theminimal
aptamer sequence of Hcy 8 may be identied. Incorporating the
minimal aptamer into this assay may further improve the
sensitivity of homocysteine detection.
Human serum also contains several other similar amino
acids that may interfere with analysis, resulting in falsely high
estimates of homocysteine concentration. We tested our sensor
against several similar amino acids, namely cysteine, methio-
nine and serine (see Fig. 4B). The concentration of target was
chosen to reect the expected concentration of homocysteine in
samples, aer the dilution step, at just above the upper refer-
ence limit. Not surprising, at 1.5 mM concentrations, minimal
response was observed with methionine and serine. However,
unlike previously developed AuNP biosensors for cysteine, our
sensor also showed little response to cysteine compared to
homocysteine (10 times signal enhancement with homo-
cysteine). At higher concentrations (greater than 3 mM), the
sensor remained selective against methionine and serine;
however, the cysteine response was more similar to homo-
cysteine (Fig. S3†). This further demonstrates that the aptamer–
target interaction dominates at concentrations closer to the
aptamer KD (1 mM) and at much higher concentrations the
gold–thiol interaction out-competes the selective aptamer–
target interaction.Conclusions
While aptamer technology has existed for over two decades,
challenges in aptamer development for small molecules have
resulted in very few aptamers for these compounds.42 As a
result, developing new aptamers for medically-relevant small
molecules is critical. We endeavoured to produce a viableThis journal is ª The Royal Society of Chemistry 2013aptamer biosensor for L-homocysteine. Eight rounds of SELEX
were performed to obtain DNA sequences displaying high
binding aﬃnity to the target, L-homocysteine. Sequence Hcy 8
bound to L-Hcy with a KD in the low micromolar range, excellent
aﬃnity considering the small size and simple structure of the
target. This sequence was also found to be selective, binding to
the similar target L-methionine and L-cysteine with 200 and 100
times less aﬃnity, respectively. With this full length sequence,
we have developed a AuNP-based biosensor able to selectively
detect low concentrations of L-homocysteine compared to other
similar amino acids. The stability and selectivity of this sensor
in serum was also conrmed, allowing for the rapid and direct
detection of homocysteine in human serum samples. Further
analysis will attempt to identify the minimal target-binding
sequence in order to shorten the aptamer and improve binding
while lowering its production cost. Adaptation of this sensor to
a lateral ow assay and other practical colorimetric assays is
ongoing.
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